1. Low expression of KCNN3 may affect drug resistance in ovarian cancer
   Xia Liu et al, 2018, Molecular Medicine Reports CrossRef
2. CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors
   Matteo Santoni et al, 2014, BioMed Research International CrossRef
3. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
   Alexandra R. Harris et al, 2018, BMC Cancer CrossRef
4. SPARCL1 impedes trophoblast migration and invasion by down-regulating ERK phosphorylation and AP-1 production and altering EMT-related molecule expression
   Xiaojing Liu et al, 2020, Placenta CrossRef
5. Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
   Concetta Altamura et al, 2021, Cancers CrossRef
6. Upregulation of NEK2 is associated with drug resistance in ovarian cancer
   XIA LIU et al, 2014, Oncology Reports CrossRef
7. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer
   XIA LIU et al, 2016, International Journal of Oncology CrossRef
8. Integrative genomic analyses of secreted protein acidic and rich in cysteine and its role in cancer prediction
   BO WANG et al, 2014, Molecular Medicine Reports CrossRef
9. Discovery of microarray-identified genes associated with ovarian cancer progression
   XIA LIU et al, 2015, International Journal of Oncology CrossRef
10. Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy
    Subhankar Bose et al, 2022, Seminars in Cancer Biology CrossRef
11. Lymphatic vasculature in ovarian cancer
    Sarit Pal et al, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
12. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer
    JIANCHAO LI et al, 2014, Oncology Reports CrossRef
13. Lipid metabolism and Calcium signaling in epithelial ovarian cancer
    Sana Kouba et al, 2019, Cell Calcium CrossRef
14. An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
    Lishuang Qi et al, 2016, British Journal of Cancer CrossRef
15. Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer
    FUQIANG YIN et al, 2014, Oncology Reports CrossRef
16. Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma
    Hao-Lun Luo et al, 2019, International Journal of Molecular Sciences CrossRef
17. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer
    Hai-Ping Zhang et al, 2022, BioMed Research International CrossRef
18. Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022
    Jiahua Liu et al, 2023, Frontiers in Oncology CrossRef
19. Downregulation of NEK11 is associated with drug resistance in ovarian cancer
    XIA LIU et al, 2014, International Journal of Oncology CrossRef
20. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer
    Yutao Gao et al, 2017, Oncology Reports CrossRef
21. Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer
    Maria E. Reyes et al, 2020, Frontiers in Immunology CrossRef
22. Associations of tumor suppressor SPARCL1 with cancer progression and prognosis
    Ting Li et al, 2017, Oncology Letters CrossRef
23. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach
    Julia Beretov et al, 2015, PLOS ONE CrossRef